surpass 1 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Read now: The SURPASS-EARLY trial

State Medicaid plans vary in their coverage of the drugs for weight loss

, , , L-

Plos One 12(7):e0181370

A perceived decrease in penis size could actually be ED, which could be a sign of cardiovascular disease or other blood flow problems

When taking GLP-1s, it's important to combine them with lifestyle changes like a balanced diet, regular exercise and stress management, as weight is often connected to several aspects of your health

Clinical trial data from the SURMOUNT studies shows that roughly 4% to 5% of people taking tirzepatide report increased hair shedding, compared with just 1% in the placebo group